The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | MRD testing prior to alloSCT can predict OS and DFS in AML
Firas El Chaer, MD, University of Virginia, Charlottesville, VA, discusses a study investigating the predictive value of measurable residual disease (MRD) testing by multiparameter flow cytometry (MFC) for patients with acute myeloid leukemia (AML) in the first complete remission (CR1). The study found that MRD testing before allogeneic stem cell transplantation (alloSCT) predicted overall survival (OS) and disease-free survival (DFS), but not treatment-related mortality (TRM). The MRD test had a positive predictive value (PPV) of 45% and a negative predictive value (NPV) of 67%. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
